Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets

You may also be interested in...



A Closer Look: Dr. Reddy’s Sees Global Leadership In Biosimilars Via Merck Serono Deal

Dr. Reddy’s CEO spoke with PharmAsia News to discuss the carefully crafted deal.

Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More

The Indian drug maker has officially kept its biosimilar pipeline secret but has indicated that it includes a pegylated molecule in late-stage clinical trials, two other products scheduled to enter clinical trials, and several others in early stage development.

Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More

The Indian drug maker has officially kept its biosimilar pipeline secret but has indicated that it includes a pegylated molecule in late-stage clinical trials, two other products scheduled to enter clinical trials, and several others in early stage development.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel